MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.
MP Advisors unparalleled service includes:
- Financial Analysis;
- Competitive landscaping;
- Macro Analysis;
- Technology Transfer;
- Mergers & Acquisitions;
- Strategic planning;
- Forecast.
Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.
More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.
Publications found:
456
Sort by:
BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
US$ 140.00
Biogen Idec (BIIB) is closing 2011 with a positive note and ... Copaxone (L, RRMS) share of the MS market. Moreover, PhIIb data readouts from SELECT trial of Daclizumab HYP (PhII, IL-2 alpha subunit ... read our report, released on Nov. 8, 2011 on “Biogen Idec - Data of BG-12 + Sales Growth Brighten 2012 Prospects”
November 2011
6 pages
ASTELLAS - Commercialization Terms Fade MDV-3100 Clinical Success for Astellas!
US$ 90.00
Astellas released solid interim data from AFFIRM trial on MDV-3100 ... this solid data, we find a limited bottom line impact on Astellas due to its commercialization agreement with Medivation. Under the agreement, Medivation will ... receive upto $650m milestone payment which leaves a little for Astellas’s investor.
November 2011
3 pages
Mature Biotech: 3Q11 Earnings Summary
US$ 90.00
In this note we summarize the 3Q earnings of Mature Biotech – ALXN, AMGN, BIIB, CELG, GILD, and ONXX. We continue to reiterate ... PhIII data in mCRC). For more details, please read our 3Q11 earnings’ summary report released on 4th Nov, 2011 on “Mature Biotech: 3Q11 Earnings Summary”.
November 2011
5 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
... ) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial ... ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for ...
October 2011
4 pages
CIPLA, Para IV Upside To Continue: Its Lexapro After Zyprexa
US$ 350.00
... of $1b) under 180-day exclusivity starting 14 March 2012. Cipla remained an active partner to Ivax (now Teva) by developing ... -day exclusivity. Thus Cipla too will share the upsides from the exclusivity. We expect Cipla to gain $50m ... will start accruing immediately after the upside from Zyprexa API supply to Teva ...
October 2011
3 pages
ASTRAZENECA - Seroquel XR: Para IV Settled with Handa, More to come
US$ 90.00
AstraZeneca today announced that it has settled paragraph IV litigation for Seroquel XR with Handa pharmaceuticals, who has the first to filer status ... settlement Handa will launch Seroquel XR generics only after November 2016. While litigation is ongoing with other Para-IV filers and a court decision ...
September 2011
2 pages
DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!
US$ 140.00
Recent failures of Edoxaban’s key competitor factor-Xa inhibitors from Japan - YM 150 (Astellas) and TAK-442 (Takeda), the closest candidate in Japan now is Xarelto ... years away from hitting the market. Edoxaban is the first and only approved factor-Xa inhibitor in Japan for prevention of VTE, though Japanese ...
September 2011
4 pages
ROCHE, GLAXOSMITHKLINE - Exciting Data on TDM1 - Will Keep Competition at Bay
US$ 140.00
... months compared to Herceptin + docetaxel (14.2 m vs. 9.2 m- Table 1). The safety data as well, is very convincing as T-DM1 cut Grade 3 or more adverse effects ... 50% (46.4% vs. 89.4%). With T-DM1 and pertuzumab arrows in its quiver, Roche is well poised to sustain its breast cancer franchise beyond Herceptin ...
September 2011
4 pages
Vertex - Near Term Positive Long Term Neutral
US$ 140.00
... therapy area is heating up, Vertex (VRTX) will continue to have the edge for at least 3yrs. We expect most of the near term milestones related for ... read our report released on 23th September, 2011 on VRTX titled “Near Term Positive Long Term Neutral”.
September 2011
5 pages
Pharmasset - Tapping Both IFN and IFN-Free Opportunities
US$ 140.00
... daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises ... NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the ... IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN ...
September 2011
7 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
We have a positive expectation for the approval of Eculizumab (L, Soliris, Paroxysmal Nocturnal Hemoglobinuria) in Atypical ... more details, please read our report released on September 16, 2011 on Alexion (ALXN), titled “Great Expectations From Label Expansion”.
September 2011
4 pages
Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class
US$ 2,000.00
Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class Bydureon – A near term growth driver of the class Novel delivery platforms and fixed ... in cumulative peak sales for this class of drugs by the turn of this decade as we see innovation efforts around this class will result in ...
September 2011
68 pages
ARQULE - Read-Out Only in 2013
US$ 140.00
... . It is an attractive acquisition target due to…. For more details, please read our report released on 13th September, 2011 on ARQL titled “Read-Out Only in 2013”.
September 2011
4 pages
PHARMASSET - Another Step Towards Success!
US$ 90.00
Pharmasset (VRUS) announced top line data of PSI-7977 PhIIb, PROTON ... read our report released on 13th September, 2011 on VRUS titled “Another Step Towards Success”.
September 2011
4 pages
ARDEA - Entering the Pivotal Phase
US$ 140.00
After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII ... in the report released on 12th September, 2011 on RDEA titled “Entering the Pivotal Phase”. For more details please ask for our initiation ...
September 2011
3 pages
Stroke Prevention in Atrial Fibrillation - View on Upcoming Milestones
US$ 90.00
DETAILED DATA FROM ARISTOTLE STUDY AT ESC – AUGUST 28th. BMY is likely to announce detailed data on Eliquis in SPAF from the ARISTOTLE study. The data on Eliquis from ARISTOTLE will be compared to the data on Pradaxa from RELY trial and not Xarelto- ROCKET AF, as there are major differences in trial design. ...
August 2011
2 pages
Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
US$ 140.00
... Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval ... , Eisai has three late stage candidates E-2007/ perampanel ...
August 2011
8 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Gilead - Complera Approval - Positive Long Term Impact
US$ 90.00
Approval of Complera (GILD’s Truvada + Tibotec’s Edurant) reiterates GILD’s ... HIV infection. With the current economic turmoil, approval of once-daily Complera (formerly Fixed Dose Combination drug) impact may ... report released on 12th August, 2011, titled – “Complera Approval - Positive Long Term Impact”
August 2011
5 pages
Aurobindo - Feeling The Heat of USFDA and Debt
US$ 140.00
We reiterate our Underperform rating on Aurobindo after Q1 FY12 result that remained ... (up by 39% and 20% of total sales) that included a Government of India tender where ARBP did not earn any profit. As expected ... API and formulations) remain at the core of ‘India advantage’. We reduce our target price to Rs.120
August 2011
6 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages